Safety and Efficacy of Medical Cannabis in Fibromyalgia
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Chronic pain may be treated by medical cannabis. Yet, there is scarce evidence to support the role of medical cannabis in the treatment of fibromyalgia. The aim of the study was to investigate the characteristics, safety, and effectiveness of medical cannabis therapy for fibromyalgia. Methods: A prospective observational study with six months follow-up period based on fibromyalgia patients who were willing to answer questionnaire in a specialized medical cannabis clinic between 2015 and 2017. Results: Among the 367 fibromyalgia patients, the mean age was 52.9 ± 15.1, of whom 301 (82.0%) were women. Twenty eight patients (7.6%) stopped the treatment prior to the six months follow-up. The six months response rate was 70.8%. Pain intensity (scale 0–10) reduced from a median of 9.0 at baseline to 5.0 (p < 0.001), and 194 patients (81.1%) achieved treatment response. In a multivariate analysis, age above 60 years (odds ratio [OR] 0.34, 95% C.I 0.16–0.72), concerns about cannabis treatment (OR 0.36, 95% C.I 0.16–0.80), spasticity (OR 2.26, 95% C.I 1.08–4.72), and previous use of cannabis (OR 2.46 95% C.I 1.06–5.74) were associated with treatment outcome. The most common adverse effects were mild and included dizziness (7.9%), dry mouth (6.7%), and gastrointestinal symptoms (5.4%). Conclusion: Medical cannabis appears to be a safe and effective alternative for the treatment of fibromyalgia symptoms. Standardization of treatment compounds and regimens are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wolfe, F., Clauw, D. J., Fitzcharles, M., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B., & Yunus, M. B. (2010) · Arthritis Care & Research · doi:10.1002/acr.20140 · Cited by 3,952 · cited 2×
“The fibromyalgia diagnosis was established by a board-certified rheumatologist according to the American College of Rheumatology preliminary diagnostic criteria for fibromyalgia [13].”
MethodThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 1×
“cannabinoid receptors and their endogenous ligands has triggered a large body of studies, there is a paucity of large-scale and prospective clinical trials regarding their role in fibromyalgia [9].”
BackgroundDuloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565 · cited 1×
“A similar pain reduction rate was shown in meta-analyses of both anticonvulsants and serotonin–noradrenalin reuptake inhibitors [16,17].”
ResultNabilone for the treatment of pain in fibromyalgia.
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.002 · Cited by 384
Adverse effects of medical cannabinoids: a systematic review
Wang, T., Collet, J.-P., Shapiro, S., & Ware, M. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071178 · Cited by 357 · cited 1×
“In concordance with the literature, we found that dizziness, dry mouth, hyperactivity, drowsiness, and gastrointestinal symptoms are all possible adverse effects of cannabis use [14,33].”
BackgroundThe Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial
Ware, M. A., Fitzcharles, M.-A., Joseph, L., & Shir, Y. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181c76f70 · Cited by 324 · cited 1×
“The authors found a moderate effect on insomnia, but not on other aspects of sleep, in addition to no improvement in pain and quality of life [11].”
BackgroundCannabis as a substitute for prescription drugs – a cross-sectional study
Corroon, J., Mischley, L., & Sexton, M. (2017) · Journal of Pain Research · doi:10.2147/jpr.s134330 · Cited by 208
An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California
Nunberg, H., Kilmer, B., Pacula, R. L., & Burgdorf, J. R. (2011) · Journal of Drug Policy Analysis · doi:10.2202/1941-2851.1017 · Cited by 121
Cited by
Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization
Casale, R., Atzeni, F., Bazzichi, L., Beretta, G., Costantini, E., Sacerdote, P., & Tassorelli, C. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00244-1 · Cited by 159
Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies
Maffei, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217877 · Cited by 150
Current and Emerging Pharmacotherapy for Fibromyalgia
Tzadok, R., & Ablin, J. N. (2020) · Pain Research and Management · doi:10.1155/2020/6541798 · Cited by 122
“+e researchers showed a significant reduction in average pain intensity, sleep disturbance, and depression-related symptoms [76].”
Background“Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations
MacCallum, C. A., Lo, L. A., & Boivin, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.002 · Cited by 71
Metadata
- Authors
- Sagy, I., Bar-Lev Schleider, L., Abu-Shakra, M., & Novack, V.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2019-06-05
- Volume
- 8
- Issue
- 6
- Pages
- 807
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2953331451
- Cited by
- 130
- References
- 8
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Medical Cannabis in Fibromyalgia. https://app.cochat.ai/papers/10.3390/jcm8060807
- The paper
- Sagy, I., Bar-Lev Schleider, L., Abu-Shakra, M., & Novack, V. (2019). Safety and Efficacy of Medical Cannabis in Fibromyalgia. Journal of Clinical Medicine. https://doi.org/10.3390/jcm8060807
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.